Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The trends in the rationale of chemotherapy for malignant lymphoma are to use combination regimen, non-cross resistant alternating regimen, and hybrid regimen. Long follow-up results of chemotherapy of lymphoma were summarized as follows: for Hodgkin's disease, MOPP regimen of 20 years from NCI in 188 patients (pts) with 84% CR rate and 54% (101 pts) relapse-free (RF) at 15 years, and MOPP-ABV hybrid regimen in 76 pts with 97% CR rate and 90% RFS rate at 7 years; for non-Hodgkin's lymphoma (NHL), results of three generations are reported: the first generations were the first generation (CHOP, BACOP, 40-50s% CR rate and 30s% long-term survivors), the second generation (Pro-MACE/MOPP, 70s% and 40-50s%) and the third generation (MACOP-B, 80s% and 60-70s%). MACOP-B regimen in 125 pts with large-cell lymphoma showed 84% CR rate and 69% RFS rate and 69% RFS rate at 6.5 years. In our studies with four regimens of VCP, AVCP, AVCP/EMLP and B-AVCR/EMVP, CR rate was 56% in 101 pts, and 26 pts are still in CR among 40 living pts. The CR rate and the RSF rate reported in Japan are generally still low for curability of NHL.
 ...
PMID:[Cancer curable by chemotherapy: malignant lymphoma]. 265 23

Thirty-one patients with advanced non-Hodgkin's lymphoma were treated with a combination chemotherapy (VCP therapy), including vincristine (1 mg, weekly), cyclophosphamide (350mg/m2, IV every two weeks) and prednisolone (60mg/day, 1-5 days PO, every two weeks), as an out-patient basis, from May 1974 to October 1977. Characteristics of 31 patients were as follows: median age (56 years), histological types by Rappaport's classification (nodular 2, diffuse 29, NPDL 2, DWDL 5, DPDL 10 and DH 14), clinical stages (II 4, III 9, IV 18), systemic symptoms (A 13, B 18), extranodal presentation (28) and prior treatment (17). Response was evaluated in 28 patients with measurable disease. Complete response (CR) was obtained in 15 patients (53%) and partial response (PR) in 5 (18%). Median time to CR was 20 (6-79) days, and response duration of CR was 14 (1.5-78+) months. Survival time was 19 (1-76) months for all patients, 26 (3-78) months for patients with CR, 9 (3-51) months for patients with PR, and 4 (1-41) months for non-responders. Survival of complete responders was significantly better than that of patients with non-CR. Survival rates of complete responders were 80% (1 year), and 47% (3 year). Toxicities of VCP therapy were relatively mild and reversible with peripheral neuropathy, hair loss and leukopenia. The results indicate that it is necessary to perform more intensive combination chemotherapy adding potent agents for a higher CR rate and a longer CR duration.
 ...
PMID:[Chemotherapy for advanced non-Hodgkin's lymphoma with CVP therapy]. 668 54